IGHE and asthma: Monoclonal antibodies including anti-IgE, anti-IL5, anti-IL5 receptor, and anti-IL4 receptor have advanced the management of severe asthma, with the choice of therapy predicated on the ability to define the endotype of asthma in the patient29.